Payment overview · 2025
General Payments
$73.18
3 reported records · 3 companies
Healthcare provider profile · identity verified
Isaac Gorbaty, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · TARZANA, CA · NPI 1477562718
Verified facts
What the public records show
CMS Open Payments records show Isaac Gorbaty, M.D. received $73.18 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 40.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.37 | 40.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.89 | 34.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.92 | 25.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $73.18 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $29.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 59 |
| Atorvastatin Calcium | Atorvastatin Calcium | 247 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 226 | 65 |
| Alprazolam | Alprazolam | 206 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 52 |
| Omeprazole | Omeprazole | 157 | 40 |
| Losartan Potassium | Losartan Potassium | 141 | 47 |
| Metformin Hcl | Metformin Hcl | 131 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 33 |
| Potassium Chloride | Potassium Chloride | 110 | 26 |
| Furosemide | Furosemide | 106 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 26 |
| Azithromycin | Azithromycin | 91 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 24 |
| Lisinopril | Lisinopril | 87 | 26 |
| Trazodone Hcl | Trazodone Hcl | 84 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 23 |
| Montelukast Sodium | Montelukast Sodium | 78 | 16 |
| Lorazepam | Lorazepam | 76 | 16 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Gabapentin | Gabapentin | 71 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 19 |
| Allopurinol | Allopurinol | 68 | 12 |
| Simvastatin | Simvastatin | 68 | 18 |
| Carvedilol | Carvedilol | 66 | 20 |
| Eliquis | Apixaban | 58 | 12 |
| Spironolactone | Spironolactone | 57 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 11 |
| Tramadol Hcl | Tramadol Hcl | 54 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 53 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 52 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | suppressed |
| Glipizide | Glipizide | 49 | 16 |
| Famotidine | Famotidine | 45 | 16 |
| Ozempic | Semaglutide | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Finasteride | Finasteride | 41 | 11 |
| Labetalol Hcl | Labetalol Hcl | 40 | 14 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 12 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | 11 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | 13 |
| Celecoxib | Celecoxib | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 14 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 15 |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Prednisone | Prednisone | 19 | 11 |
| Restasis | Cyclosporine | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ssd | Silver Sulfadiazine | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $73.18 · 3 records | ABBVIE INC. | CREON, GVOKE HYPOPEN, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error